Prof Dr. med. Ulrich Keller

AG Ulrich Keller
Med. Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie (CBF)
Charité-Universitätsmedizin Berlin
Tibor-Diamantstein-Haus, Haus IB
Hindenburgdamm 30
12203 Berlin
Tel: +49 30 450 513 381
E-Mail: ulrich.keller(at)charite.de

Scientific Scope

Mechanism-based cancer therapies

Myc-associated cancer biology
Functional genomic screening
Aberrant Ub/SUMO activity in cancer
Chemokine receptor signaling
Functional imaging and theranostics

Group Members

Team (Charité  and TUM):

Markus Schick, Postdoc (TUM/Charité)
Matthias Wirth, Dr. rer. nat., Postdoc (Charité)
Stefan Habringer, Dr. med. Dr. univ., Clinician scientist (Charité)
Jolanta Slawska, M.Sc. (TUM)

Konstandina Isaakidis, M.Sc. (Charité)
Veronika Schulze, M.Sc. (Charité)
Chary Nimmagada, Dr. rer. nat., Postdoc (Charité)
Nikita Nikita, PhD student (Charité)
Le Zhang, MD student (Charité)
Yingfen Hong, MD student (TUM)
Josefina Doffo, PhD student (Charité)

Elena Rohleder, Dr. med., Clinician scientist (Charité)
Sven Liebig, Clinician scientist (Charité)

Uta Demel, Dr. med., Clinician scientist (Charité)
Josefina Doffo, PhD student (Charité)

Richard Lewis, MD student (TUM)
Stavroula Litsiou (Charité)

Selected References

  • Weber J, de la Rosa J, Grove CS, Schick M, Rad L, Baranov O, Strong A, Pfaus A, Friedrich MJ, Engleitner T, Lersch R, Öllinger R, Grau M, Menendez IG, Martella M, Kohlhofer U, Banerjee R, Turchaninova MA, Scherger A, Hoffman GJ, Hess J, Kuhn LB, Ammon T, Kim J, Schneider G, Unger K, Zimber-Strobl U, Heikenwälder M, Schmidt-Supprian M, Yang F, Saur D, Liu P, Steiger K, Chudakov DM, Lenz G, Quintanilla-Martinez L, Keller U, Vassiliou GS, Cadiñanos J, Bradley A, Rad R. PiggyBac transposon tools for recessive screening identify B-cell lymphoma drivers in mice. Nat Commun. 2019
  • Philipp-Abbrederis K, Herrmann K, Knop S, Schottelius M, Eiber M, Lückerath K, Pietschmann E, Habringer S, Gerngroß C, Franke K, Rudelius M, Schirbel A, Lapa C, Schwamborn K, Steidle S, Hartmann E, Rosenwald A, Kropf S, Beer AJ, Peschel C, Einsele H, Buck AK, Schwaiger M, Götze K, Wester HJ, Keller U. In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma. EMBO Mol Med. 2015

  • Dechow T, Steidle S, Götze KS, Rudelius M, Behnke K, Pechloff K, Kratzat S, Bullinger L, Fend F, Soberon V, Mitova N, Li Z, Thaler M, Bauer J, Pietschmann E, Albers C, Grundler R, Schmidt-Supprian M, Ruland J, Peschel C, Duyster J, Rose-John S, Bassermann F, Keller U. GP130 activation induces myeloma and collaborates with MYC. J Clin Invest. 2014

  • Hoellein A, Fallahi M, Schoeffmann S, Steidle S, Schaub FX, Rudelius M, Laitinen I, Nilsson L, Goga A, Peschel C, Nilsson JA, Cleveland JL, Keller U. Myc-induced SUMOylation is a therapeutic vulnerability for B-cell lymphoma. Blood. 2014

  • den Hollander J, Rimpi S, Doherty JR, Rudelius M, Buck A, Hoellein A, Kremer M, Graf N, Scheerer M, Hall MA, Goga A, von Bubnoff N, Duyster J, Peschel C, Cleveland JL, Nilsson JA, Keller U. Aurora kinases A and B are up-regulated by Myc and are essential for maintenance of the malignant state. Blood. 2010